Anxious and non-anxious major depressive disorder in the World Health Organization World Mental Health Surveys

Datos Bibliográficos

ID23322004
AutoresR C Kessler (0000-0003-4831-2305, Harvard University, autor de correspondencia), Nancy A Sampson (0000-0003-2971-6072, Harvard University), Patricia A Berglund (0000-0001-5952-6021, University of Michigan), P Berglund, M J Gruber (0000-0002-6315-9284, Harvard University), A Al-Hamzawi (University of Al-Qadisiyah), Laura Helena Andrade (0000-0002-2362-3521, Universidade de São Paulo), L Andrade, Brendan Bunting (0000-0002-7219-6773, University of Ulster), Koen Demyttenaere (0000-0001-5331-487X, KU Leuven), S Florescu (National School of Public Health, Management and Professional Development), Giovanni De Girolamo (0000-0002-1611-8324, University of Brescia), Oye Gureje (0000-0003-0094-5947, University of Ibadan), Y He (0000-0002-0619-1579, Shanghai Jiao Tong University), C Hu (0000-0002-6080-5594, Shenzhen KangNing Hospital), Ying Huang (0000-0003-3569-7576, Peking University), Elie G Karam (0000-0002-4681-8225, University of Balamand), E Karam, Viviane Kovess-Masféty (0000-0001-7045-6175, École des Hautes Études en Santé Publique), S Lee (0000-0001-9257-9643, Chinese University of Hong Kong), Daphna Levinson (Israel Ministry of Health), María Elena Medina Mora (Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz), Jacek Moskalewicz (0000-0001-9658-8272, Institute of Psychiatry and Neurology), Yoshihiro Nakamura (0000-0003-1130-538X, Jichi Medical University), F Navarro-Mateu, Fernando Navarro‐Mateu (0000-0002-3228-623X, Servicio Murciano de Salud), Mark A Oakley Browne (0000-0002-7508-1015, University of Tasmania), Marina Piazza (0000-0002-8446-6419, National Institute of Quality), J Posada-Villa, J Posada‐Villa (Universidad Colegio Mayor de Cundinamarca), Tim Slade (0000-0002-1725-9188, UNSW Sydney), M ten Have (Institute of Mental Health), Yisel Torres (0000-0002-6712-365X, Universidad CES), Gemma Vilagut (0000-0002-3714-226X, Hospital del Mar Research Institute), Miguel Xavier (0000-0003-2698-1284, Universidade Nova de Lisboa), Zahari Zarkov (0000-0002-8444-3735, National Center of Public Health and Analyses), Victoria Shahly (Harvard University), M A Wilcox, Marsha Wilcox (0000-0001-8339-8621, Janssen (United States))
Año2015
Volumen24
Número3
Páginas210-226
Fecha de publicación2015-06-01
Peer ReviewedSí
Open AccessSí
TipoARTICLE
RevistaEpidemiology and Psychiatric Sciences (JOURNAL)
Identificadores de la revistaISSN: 2045-7960 • E-ISSN: 2045-7979
EditorialCambridge University Press (CUP) (PUBLISHER)
DOI10.1017/s2045796015000189
PMID25720357
OpenAlexW1974820251
IdiomaEN
Citas recibidas69
Referencias citadas59

Background. To examine cross-national patterns and correlates of lifetime and 12-month comorbid DSM-IV anxiety disorders among people with lifetime and 12-month DSM-IV major depressive disorder (MDD). Method. Nationally or regionally representative epidemiological interviews were administered to 74 045 adults in 27 surveys across 24 countries in the WHO World Mental Health (WMH) Surveys. DSM-IV MDD, a wide range of comorbid DSM-IV anxiety disorders, and a number of correlates were assessed with the WHO Composite International Diagnostic Interview (CIDI). Results. 45.7% of respondents with lifetime MDD (32.0–46.5% inter-quartile range (IQR) across surveys) had one of more lifetime anxiety disorders. A slightly higher proportion of respondents with 12-month MDD had lifetime anxiety disorders (51.7%, 37.8–54.0% IQR) and only slightly lower proportions of respondents with 12-month MDD had 12-month anxiety disorders (41.6%, 29.9–47.2% IQR). Two-thirds (68%) of respondents with lifetime comorbid anxiety disorders and MDD reported an earlier age-of-onset (AOO) of their first anxiety disorder than their MDD, while 13.5% reported an earlier AOO of MDD and the remaining 18.5% reported the same AOO of both disorders. Women and previously married people had consistently elevated rates of lifetime and 12-month MDD as well as comorbid anxiety disorders. Consistently higher proportions of respondents with 12-month anxious than non-anxious MDD reported severe role impairment (64.4 v. 46.0%; χ 2 1 = 187.0, p v. 8.9%; χ 2 1 = 71.6, p v. 45.4%; χ 2 1 = 108.8, p v. 20.6%; χ 2 1 = 11.7, p Conclusions. Patterns and correlates of comorbid DSM-IV anxiety disorders among people with DSM-IV MDD are similar across WMH countries. The narrow IQR of the proportion of respondents with temporally prior AOO of anxiety disorders than comorbid MDD (69.6–74.7%) is especially noteworthy. However, the fact that these proportions are not higher among respondents with 12-month than lifetime comorbidity means that temporal priority between lifetime anxiety disorders and MDD is not related to MDD persistence among people with anxious MDD. This, in turn, raises complex questions about the relative importance of temporally primary anxiety disorders as risk markers v. causal risk factors for subsequent MDD onset and persistence, including the possibility that anxiety disorders might primarily be risk markers for MDD onset and causal risk factors for MDD persistence.

Anxiety · Anxiety disorder · CIDI · Depression (economics) · Generalized anxiety disorder · Major depressive disorder · Mental health · Mood · Panic disorder · Poison control · Prevalence of mental disorders · Psychiatry · Suicidal ideation · Suicide prevention · Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes · Clinical Psychology · Medicine · Mental Health Treatment and Access · Psychology · Treatment of Major Depression